Ginkgo Bioworks Holdings (DNA)vsEli Lilly and Company (LLY)
DNA
Ginkgo Bioworks Holdings
$9.37
0.00%
HEALTHCARE · Cap: $518.02M
LLY
Eli Lilly and Company
$1,169.33
+4.86%
HEALTHCARE · Cap: $1.02T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 47621% more annual revenue ($72.25B vs $151.40M). LLY leads profitability with a 35.0% profit margin vs -201.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
DNA
Avoid29
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-8.0%
Fair Value
$8.66
Current Price
$9.37
$0.71 premium
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -68.7% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 33.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
DNA profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.78 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 29/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide range of sectors, including pharmaceuticals, agriculture, and industrial biotechnology. The company's innovative platform streamlines cellular design and manufacturing, positioning Ginkgo as a key player in addressing critical global challenges such as climate change and food security. With a strong focus on sustainable biotechnology solutions, Ginkgo is well-equipped to tap into the increasing market demand for bio-based alternatives, highlighting its potential for significant growth and transformative impact across various industries.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?